

Item: 9.3

INTEGRATED AUDIT AND GOVERNANCE COMMITTEE

MEETING HELD ON 11 SEPTEMBER 2018

ASSURANCE REPORT

INTRODUCTION

This is the Chair's assurance report to the Clinical Commissioning Group Board following the Integrated Audit and Governance Committee meeting held on 11 September 2018.

AUDIT

Minute No. 7.1 INTERNAL AUDIT PROGRESS REPORT

The Board can be assured of satisfactory progress and outcomes in delivering the Internal Audit Plan, which continues to represent appropriate coverage as part of the wider assurance framework.

The Board can be assured that an audit of Patient and Stakeholder Engagement had provided **substantial assurance** that controls relating to the operation and management of the CCG's communications and patient engagement processes were operating adequately and effectively and there had been no major issues to report.

The Board can be assured, as part of the 2017/18 Internal Audit Plan, that an advisory review of the CCG's committee arrangements had been carried out.

Minute No. 7.2 INTERNAL AUDIT ANNUAL REPORT 2017/18

The Board can be assured that the Internal Audit Annual Report 2017/18 had provided the CCG with an overall level of **substantial assurance**.

FINANCIAL GOVERNANCE

Minute No. 8.1 FINANCIAL REPORT

The Board can be assured that the CCG is currently forecasting to achieve a balanced position against the in year allocation and there is therefore no impact on the CCG's historic surplus of £15.267m, which is in line with the 2018/19 financial plan submitted to NHS England.

The 2018/19 running cost allocation was £6.21m and the current forecast is that expenditure will be contained within this financial envelope.

Minute No. 8.2 REVIEW OF LOSSES AND SPECIAL PAYMENTS

The Board can be assured that appropriate systems and processes are in place to discuss and declare any losses reported and special payments made. None had been reported or made.

GOVERNANCE

Minute No. 9.2 BOARD ASSURANCE FRAMEWORK 2018/19

The Board can be assured that IAGC Members had considered and discussed the updates provided against the assessed risks on the Board Assurance Framework which related to the CCG's 2018/19 strategic objectives.

Minute No. 9.3 CORPORATE RISK REGISTER

The Board can be assured that systems and processes are in place to identify and manage risks on the Risk Register. The IAGC are kept updated on any movements, provided with the opportunity to review and comment and approve the removal of any risks from the Risk Register.

Minute No. 9.4 FREEDOM OF INFORMATION REQUESTS Q1 REPORT

The Board can be assured that the CCG has a process in place to respond to all FOI requests received. There had been no missed requests during the period April 2018 to June 2018 and the CCG had achieved 100% compliance with the 20 day response deadline.

Minute No. 9.5 EMERGENCY PREPAREDNESS, RESILIENCE AND RESPONSE/BUSINESS CONTINUITY MANAGEMENT (EPRR/BCM) ANNUAL REPORT

The Board can be assured that, from the Emergency Preparedness, Resilience and Response/Business Continuity Management (EPRR/BCM) work which had taken place throughout the year, the CCG has maintained its ability to maintain its core business at all times and to act as a system leader during a national or local incident affecting how organisations provide their services.

Minute No. 9.6 INDIVIDUAL FUNDING REQUEST (IFR) PANEL TERMS OF REFERENCE (ToR) AND INDIVIDUAL FUNDING REQUEST (IFR) APPEALS PANEL TERMS OF REFERENCE (ToR)

The Board can be assured that the CCG has updated its Terms of Reference for the IFR Panel and the IFR Appeals Panel which are in line with updated IFR Policy

Minute No. 10.1i HISTORICAL PHARMACEUTICAL CASE/UPDATE REPORT

The Board can be assured that, in relation to the historical pharmaceutical case, this had now been passed through to the CPS for their opinion and a response was awaited. No further work on this case was required by the CCG.

Minute No. 10.1ii PRIMARY CARE PRESCRIBING REBATE OFFER – FLUTICASONE/SALMETEROL (SERETIDE)

The Board can be assured that the CCG has an agreed process in place to consider and approve any Primary Care Rebate Schemes for the CCG.

Following full consideration and subsequent recommendation by the Planning and Commissioning Committee, the Integrated Audit and Governance Committee formally approved the Primary Care Prescribing Rebate Scheme for Fluticasone/Salmeterol (Seretide).



Karen Marshall (Chair)
Integrated Audit and Governance Committee
11 September 2018